Telix QSAM, Inc. engages in the research of nuclear medicines for the treatment of cancer and related diseases and conditions. It also focuses on the development of its licensed radiopharmaceutical drug candidate, CycloSam. The company was founded on May 2, 2024 and is headquartered in Austin, TX.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company